Showing 4271-4280 of 5957 results for "".
- Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-receives-fda-clearance-of-ind-application-for-atsn-201-an-investigational-gene-therapy-for-the-treatment-of-x-linked-retinoschisis/2481580/Atsena Therapeutics, a clinical-stage gene therapy company, announced the FDA has cleared the company’s investigational new drug (IND) application for a phase 1/2 clinical trial of ATSN-201 in patients with X-linked retinoschisis (XLRS). ATSN-201 leverages one of the company&rsquo
- Japanese Drugmaker Astellas Pharma Acquires Iveric Bio for $5.9 Billionhttps://modernod.com/news/japanese-drugmaker-astellas-pharma-acquires-iveric-bio-for-59-billion-1/2481577/Japan-based Astellas Pharma announced it is acquiring Iveric Bio, maker of a geographic atrophy drug in late-stage development, for $5.9 billion. Under terms of the agreement, the companies entered into a definitive agreement under which Berry Merger Sub Inc., a wholly-owned subsidiary
- Medical Consulting Group and Corcoran Consulting Group Announce Mergerhttps://modernod.com/news/medical-consulting-group-and-corcoran-consulting-group-announce-merger/2481571/Medical Consulting Group (MCG), a provider of consulting services to ophthalmic practices and companies, and Corcoran Consulting Group (CCG), a company specializing in billing, coding, and reimbursement issues for ophthalmology and optometry practices, today announced a definitive merger agreemen
- Lumibird Launches Tango Neo and UltraQ Reflex Neo Lasershttps://modernod.com/news/lumibird-launches-tango-neo-and-ultraq-reflex-neo-lasers/2481570/Following the launch of its flagship product, the Tango Reflex Neo, in December 2022, Lumibird Medical announced the launch of two additional variants within its premium Nd:YAG/SLT laser range—the UltraQ Reflex Neo and Tango Neo. A fully integrated Q-switched Nd:YAG lase
- Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase 1/2 Clinical Trial of ATSN-101 in Patients with LCA1https://modernod.com/news/atsena-therapeutics-announces-positive-6-month-data-from-ongoing-phase-12-clinical-trial-of-atsn-101-in-patients-with-lca1/2481563/Atsena Therapeutics announced positive 6-month safety and efficacy data from the ongoing phase 1/2 clinical trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). The data were presented by Chris
- Zeiss Receives FDA Approval of the CT Lucia 621P Monofocal IOLhttps://modernod.com/news/zeiss-receives-fda-approval-of-the-ct-lucia-621p-monofocal-iol/2481561/Zeiss announced that the FDA has approved the CT Lucia 621P monofocal IOL, an aspheric, monofocal, single-piece C-loop IOL. The IOL features the patented Zeiss Optic (ZO) Asphericity Concept, which is designed to compensate for a wide range of spherical aberrations and at
- Johnson & Johnson Vision Showcases 30 New Sets of Scientific Data on Myopia, Refractive Technologies, IOLs and More at ARVOhttps://modernod.com/news/johnson-johnson-vision-showcases-30-new-sets-of-scientific-data-on-myopia-refractive-technologies-iols-and-more-at-arvo/2481554/Johnson & Johnson Vision announced that it is presenting 30 sets of research spanning the spectrum of eye health including myopia, refractive technology, sphere, intraocular lenses, astigmatism, consumer eye health, and vision science at the Association for Research in Vision and Ophthalmolog
- Apellis Presents Phase 3 Functional Analyses of Syfovre for Geographic Atrophyhttps://modernod.com/news/apellis-presents-phase-3-functional-analyses-of-syfovre-for-geographic-atrophy/2481553/Apellis Pharmaceuticals announced post hoc analyses from the 24-month, phase 3 OAKS and DERBY studies evaluating Syfovre (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The analyses were reported during oral presenta
- Azura Ophthalmics to Present New Data on AZR-MD-001 in Meibomian Gland Dysfunction at ASCRS and ARVOhttps://modernod.com/news/azura-ophthalmics-to-present-new-data-on-azr-md-001-in-meibomian-gland-dysfunction-at-ascrs-and-arvo/2481544/Azura Ophthalmics announced multiple presentations featuring positive efficacy and safety data from a phase 2b study of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD). Data will be featured at the upcoming Annual Meetings for the Association for Research
- Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Trial of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-announces-positive-topline-clinical-data-from-phase-3-trial-of-brimochol-pf-for-the-treatment-of-presbyopia/2481543/Visus Therapeutics reported positive topline results from its phase 3 pivotal BRIO-I trial. BRIO-I met the prespecified primary study endpoints agreed upon with the FDA and EMA/MHRA, demonstrating contribution of elements for the once-daily, fixed-dose combination, Brimochol PF, over both ac